求助：alzhemed(tramiprosate)有没有在中国申请专利

内容如题，希望大家能帮我，我找了很久还是没有找到

好像没有，呵呵，就当我什么都没有说

说来容易啊，有时候化合物的专利很难找到，而且我对专利的检索不是特别精通，所以才求助大家的。希望不要误解，我也找了好久，没有办法才发帖。

alzhemed是加拿大NEUROCHEM INTERNATIONAL LTD 公司的专利。
1  Vaccine for the prevention and treatment of Alzheimer\'s and amyloid related diseases in my patents list   
   Inventor: CHALIFOUR ROBERT; KONG XIANQI; (+2)  Applicant: NEUROCHEM INTERNATIONAL LTD
   EC:  A61K39/00D3; C07K14/47A3; (+1) IPC: A61K39/00; A61P25/28; C07K14/47 (+8)
   Publication info: NZ540564 - 2007-04-27

2  THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES in my patents list   
   Inventor: GERVAIS FRANCINE (CA); BELLINI FRANCESCO (CA)  Applicant: NEUROCHEM INTERNATIONAL LTD (CH); GERVAIS FRANCINE (CA); (+1)
   EC:  IPC:   
   Publication info: WO2007049098 - 2007-05-03

3  AMIDINE DERIVATIVES FOR TREATING AMYLOIDOSIS in my patents list   
   Inventor: WU XINFU (CA); KONG XIANQI (CA); (+1)  Applicant: NEUROCHEM INTERNATIONAL LTD (CH)
   EC:  IPC: A61K31/155; A61K31/167; A61K31/18 (+13)
   Publication info: CA2552094 - 2005-09-01

4  THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES. in my patents list   
   Inventor: BELLINI FRANCESCO (CA)  Applicant: NEUROCHEM INTERNATIONAL LTD (CH)
   EC:  A61K31/185; A61K31/445; (+2) IPC: A61K31/185; A61K31/445; A61K38/17 (+10)
   Publication info: MXPA05006940 - 2006-02-22

5  VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER\'S AND AMYLOID RELATED DISEASES in my patents list   
   Inventor: GERVAIS FRANCINE (CA); HEBERT LISE (CA); (+2)  Applicant: NEUROCHEM INTERNATIONAL LTD (GI)
   EC:  A61K39/00D3; C07K14/47A3; (+1) IPC: A61K39/00; A61P9/00; A61P25/28 (+10)
   Publication info: EP1392728 - 2004-03-03

6  METHOD FOR MODULATING MACROPHAGE ACTIVATION. in my patents list   
   Inventor: MORISSETTE CELINE (CA)  Applicant: NEUROCHEM INC (CA)
   EC:  A61K31/00 IPC: C12N5/10; A61K31/00; A61K31/185 (+29)
   Publication info: MXPA00007815 - 2002-04-24



以上这些专利可以给你提供帮助

补充：只要查到国外申请的专利在利用同族专利查国内专利申请公开。
Another such method of treatment that has been proposed is that of administering a compound which blocks the aggregation of A.beta.. Compounds having this property include chelating agents such as clioquinol (Gouras and Beal, Neuron, 30 (2001), 641-2) and the compounds disclosed in WO 99/16741, in particular that known as DP-109 (Kalendarev et al, J. Pharm. Biomed. Anal., 24 (2001), 967-75). Other inhibitors of A.beta. aggregation include the compounds disclosed in WO 96/28471, WO 98/08868 and WO 00/052048, including the compound known as Apan.TM. (Praecis), WO 00/064420, WO 03/017994, WO 99/59571 and the compound known as Alzhemed.TM. (Neurochem), WO 00/149281 and the compositions known as PTI-777 and PTI-00703 (ProteoTech), WO 96/39834, WO 01/83425, WO 01/55093, WO 00/76988, WO 00/76987, WO 00/76969, WO 00/76489, WO 97/26919, WO 97/16194, and WO 97/16191.

多谢多谢